<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389815</url>
  </required_header>
  <id_info>
    <org_study_id>WX0593-001</org_study_id>
    <nct_id>NCT03389815</nct_id>
  </id_info>
  <brief_title>A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients</brief_title>
  <official_title>The Dose-escalation Study Followed by an Extension Phase Evaluating the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients With Anaplastic Lymphoma Kinase（ALK）/Receptor Tyrosine Kinase（ROS1） Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593
      alone in the treatment of advanced cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first part is a single-arm, phase 1, open label, dose-escalation design in patients with
      anaplastic lymphoma kinase（ALK）/receptor tyrosine kinase（ROS1） Positive ALK/ROS1-positive
      solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC)
      characterized by abnormalities in anaplastic lymphoma kinase(ALK) expression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose（MTD）</measure>
    <time_frame>28 days</time_frame>
    <description>The MTD is determined by the number of the participants in cohort who suffer a dose-limiting toxicity (DLT). The MTD is defined as the former dose at which more than one third of the participants develop a DLT. If no DLTs are observed, the MTD is not reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics of WX-0593 by assessment of time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics of WX-0593 by assessment of maximum plasma WX-0593 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics of WX-0593 by assessment of minimum plasma WX-0593 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics of WX-0593 by assessment of area under the plasma concentration time curve from zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tl/2 of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics of WX-0593 by assessment of the terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cssmin of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Cmin of WX-0593 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cssmax of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Cmax of WX-0593 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css-av of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Mean plasma concentration of WX-0593 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>area under the curve of WX-0593 at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DF of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics of WX-0593 by assessment of degree of fluctuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>volume of distribution during terminal phase after WX-0593 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLs of WX-0593</measure>
    <time_frame>28 days</time_frame>
    <description>total plasma,serum or blood clearance of WX-0593 after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From fist administration of WX-0593 to 28 days after last medication.</time_frame>
    <description>Primary efficacy endpoint is a change in the proportion of subjects showing overall objective response rate (ORR) from baseline to final tumor assessment point after treatment. As Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, the percentage of subjects indicating PR (partial response) and CR (complete response) will be calculated.
According to RECIST 1.1 criteria, complete response (CR) - the disappearance of all target lesions and partial response ( PR ) - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From fist administration of WX-0593 to 28 days after last medication.</time_frame>
    <description>PFS defined as the time from baseline to first observed disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From fist administration of WX-0593 to 28 days after last medication.</time_frame>
    <description>DCR is the percentage of patients with best response of CR, PR or Stable Disease (SD).
SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) and so on</measure>
    <time_frame>From fist administration of WX-0593 to 28 days after last medication.</time_frame>
    <description>The DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date on which progressive disease (PD) is first noted or date of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumor, Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>WX-0593 Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WX-0593 Tablets</intervention_name>
    <description>tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）</description>
    <arm_group_label>WX-0593 Tablets</arm_group_label>
    <other_name>FL-006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 70 years, inclusive.

          2. Female or male

          3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

          4. Life expectancy of at least 12 weeks.

          5. At least one measurable lesion (according to RECIST v1.1)

          6. Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy
             with ALK/ROS1+ (For the expansion phase, patients must have NSCLC with ALK+ ):

               -  Patients with advanced tumor (eg. NSCLC, lymphoma, inflammatory myofibroblastic
                  tumor) who failed in standard treatment (eg. resistant of ALK inhibitors or
                  chemotherapy)

               -  Patients with advanced NSCLC who cannot accept chemotherapy or intolerance with
                  chemotherapy.

               -  Advanced NSCLC patients who could not afford ALK inhibitor treatment.

          7. Patients with treated or untreated asymptomatic Central Nervous System（CNS） metastases
             may be allowed to enroll.

          8. Patients must have normal function as defined: ANC≥1.5*10^9/L PLT≥100*10^9/L， Total
             Bilirubin （TBIL）≤1.5*Upper Limit of Normal（ULN） ( Gilbert's Syndrome TBIL ≤3.0*ULN and
             DBIL≤1.5*ULN )，Alanine Transaminase （ALT）and Aspartate Aminotransferase（AST）≤2.5*ULN.
             For liver metastasis patients, ALT and AST≤5*ULN, Cr≤1.5*ULN, LVEF≥50%.

          9. Any surgery or radiation (expect for palliative radiation) must have been completed at
             least 4 weeks prior to first dosing. Palliative radiation must have been completed at
             least 48 hours prior to first dosing.

         10. All related adverse events from previous anti-cancer therapies must have recovered to
             ≤ Grade 1 (except for alopecia).

         11. Patients must be able to understand and volunteer to sign the informed consent.

        Exclusion Criteria:

          1. Clinically significant cardiovascular disease within 3 months prior to first dosing.

          2. Ongoing cardiac dysrhythmias, or any grade of uncontrolled atrial fibrillation, or
             prolonged QT interval (QTc &gt; 480 ms).

          3. Patients need medications that may prolong QT interval or induce torsades de pointes
             within 14 days prior to the first dosing or during the study.

          4. Peripheral neuropathy ≥ Grade 3 according to CTCAE 4.03.

          5. Patients who received continuous use of steroids for more than 30 days, or who need
             long-term use of steroid hormones or other immunosuppressive agents.

          6. History of extensive disseminated/bilateral pulmonary interstitial fibrosis,
             interstitial fibrosis or interstitial lung disease of Grade 3/4 .

          7. Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             WX-0593.

          8. Patients who are receiving warfarin sodium (Coumadin) or any other coumadin-derived
             anticoagulants，and patients with coagulation disturbance and bleeding tendency.

          9. Patient has received other investigational drug within 1 month.

         10. Patients with acute or chronic infectious medical conditions, including active
             hepatitis (Hepatitis A、 Hepatitis B、 Hepatitis C ) or HIV infection.

         11. Patients who received prior anti-cancer therapy within 2 weeks (t1/2 ≤ 3 days) or
             within 4 weeks (3 days ＜ t1/2）. Patients previously treated with crizotinib could
             start WX-0593 dosing after 1 week from the last dosing.

         12. Patients who could not discontinue therapy with potent CYP3A4 inhibitors or inducers
             within 1 week prior first dosing, or patients who need therapy with CYP3A4 inhibitors
             or inducers during the study.

         13. Patients received medications known to be metabolized by CYP3A4 and with narrow
             therapeutic indices, who could not discontinue within 1 week prior to the start of
             WX-0593 administration. Patients who need therapy with those medications during the
             study.

         14. Females who are pregnant or breastfeeding.

         15. Patients with childbearing potential must agree to use adequate contraception for the
             duration of treatment and for 6 months after the study.

         16. Drug abusers and alcoholics.

         17. History of definite nerves or psychosis diseases including epilepsy or dementia.

         18. History of other malignancy.

         19. Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol or would impart excessive risk associated with study participation
             that would make it inappropriate for the patient to be enrolled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Fang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shucai Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chest Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunpeng Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, M.D.</last_name>
      <phone>86-010-87788293</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

